PT - JOURNAL ARTICLE AU - PSM Writing Group AU - PSM Consortium Group AU - Turaga, Kiran K TI - Consensus Guideline for the Management of Patients with Peritoneal Mesothelioma AID - 10.1101/2024.04.10.24305432 DP - 2024 Jan 01 TA - medRxiv PG - 2024.04.10.24305432 4099 - http://medrxiv.org/content/early/2024/04/13/2024.04.10.24305432.short 4100 - http://medrxiv.org/content/early/2024/04/13/2024.04.10.24305432.full AB - Background Treatment of peritoneal mesothelioma (PeM) poses significant challenges owing to its rare incidence, heterogeneity and limited clinical evidence. This manuscript describes results from a national consensus aimed at addressing management of PeM.Methods An update of the 2018 Chicago Consensus Guidelines was conducted using a Modified Delphi technique, encompassing two rounds of voting. The levels of agreement for various pathway blocks were assessed.Results Of 101 participants responding in the first round of Modified Delphi voting, 95 (94%) responded in the second round. Over 90% consensus was achieved in 5/6 and 6/6 pathway blocks in rounds I and II, respectively. Observation was recommended for benign neoplasms, with guidance for interventions in the presence of symptoms or concerning clinicopathologic features. For malignant pathology, management was outlined based on a multidisciplinary assessment of patient characteristics, disease histology, and predictive success of medical and surgical interventions. Additional emphasis was placed on multimodal therapy for Intermediate-Risk and appropriate High-Risk patients. A rapid review demonstrated limited availability of data and inconclusive findings regarding optimal systemic therapy timing. There was unanimous support for considering clinical trial enrollment.Conclusions Given limited evidence, the consensus-driven pathway provides essential guidance regarding the management of PeM. To further direct clinical care, additional dedicated research to generate higher-quality evidence is needed.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.